Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Interest Income

Income earned on cash, deposits, and investments held by the company.

Janux Therapeutics, Inc.NASDAQ: JANX

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q1 FY2026 interest income of $9.85M fell 13.5% year over year, behind the +84.4% change in trailing-twelve-month interest income. Sequentially, it fell 71.1% from the prior quarter. Over 3 fiscal years it compounded at +121.9% a year.

Context

  • Interest income amounted to 440.4% of revenue in FY2025, up 158.5 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of +84.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.85M-71.1% QoQ
Last fiscal yearDec 2025
$44.04M+47.5% YoY
LTMMar 2026
$66.09M+84.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.5%——
1 year+47.5%——
3-year CAGR+121.9%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
44.04M USD
Year-over-year change
+47.5%
4-year CAGR
+261.8%

Interest Income vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +84.4% is the highest of 10, against a peer median of -29.4%.
  • Interest income amounts to 305.8% of revenue for JANX, versus a peer median of 11.9%.
JANX Competitors
Interest Income for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JANXJanux Therapeutics, Inc.LTM Mar 2026$66.09M USD+84.4%+121.9%305.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.4M USD-19.9%+114.3%22679.5%
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M USD-48.6%+69.9%1.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$19.73M USD-35.4%+49.8%—
IMNMImmunome, Inc.LTM Sep 2026$18.04M USD+57.2%+1228.3%—
IMTXImmatics N.V.LTM Mar 2026€15.3M EUR-36.7%+90.7%41.0%
STROSutro Biopharma, Inc.LTM Mar 2026$7.7M USD-80.3%+38.9%7.7%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$7M USD+5.2%+39.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$5.74M USD-2.6%+45.8%16.2%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-29.4%+49.8%11.9%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.